Gil Bar‐Sela

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher et al. · Nature Medicine · 2019 · 319 citations

Medicine, Melanoma, Immune Checkpoint Inhibitor +4

Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer

Ron Epelbaum, Moshe Schaffer, B. Vizel et al. · Nutrition and Cancer · 2010 · 275 citations

Art therapy improved depression and influenced fatigue levels in cancer patients on chemotherapy

Gil Bar‐Sela, Lily Atid, Sara Danos et al. · Psycho-Oncology · 2007 · 230 citations

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov et al. · The Lancet Oncology · 2018 · 210 citations · Full text

Medicine, Melanoma, Immunology +10